Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 2:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 96 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Overactive Bladder (OAB) Clear all
Terminated Not applicable Interventional

Condensed Percutaneous Tibial Nerve Stimulation (PTNS) Protocol

NCT03559946
View directory record Official record
Conditions
Overactive Bladder Syndrome
Interventions
percutaneous tibial nerve stimulation (PTNS), Sham procedure
Device
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 8, 2026, 2:38 AM EDT
Completed Phase 4 Interventional

A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men.

NCT00333112
View directory record Official record
Conditions
Urinary Incontinence
Interventions
solifenacin succinate, tamsulosin, placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
45 Years and older · Male only
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
74
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tuscon, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Sep 8, 2026, 2:38 AM EDT
Completed Not applicable Interventional Results available

Clinical Trial to Study a Non-invasive Neurostimulation Device on Urgency (Urinary) Incontinence Overactive Bladder (OAB)

NCT01125722
View directory record Official record
Conditions
Overactive Bladder
Interventions
Non-invasive neurostimulation device
Device
Lead sponsor
Ethicon Endo-Surgery
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Royal Oak, Michigan • Lawrenceville, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2012 · Synced Sep 8, 2026, 2:38 AM EDT
Completed Phase 2 Interventional

Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women

NCT03475706
View directory record Official record
Conditions
Overactive Bladder
Interventions
Solabegron immediate release tablets, low dose, Solabegron immediate release tablets, high dose, Matching Placebo
Drug
Lead sponsor
Velicept Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
86
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 77 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Sep 8, 2026, 2:38 AM EDT
Recruiting Phase 2Phase 3 Interventional

Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms

NCT05878951
View directory record Official record
Conditions
Urinary Incontinence, Overactive Bladder Syndrome, Overactive Bladder, Urologic Diseases
Interventions
OnabotulinumtoxinA
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 8, 2026, 2:38 AM EDT
Recruiting No phase listed Observational

Intradetrusor Onabotulinumtoxin A (Botox) at the Time of Transurethral Resection of the Prostate or Transurethral Waterjet Ablation of the Prostate for Mixed Lower Urinary Tract Symptoms

NCT07377929
View directory record Official record
Conditions
Benign Prostatic Hypertrophy (BPH), Lower Urinary Track Symptoms
Interventions
Survey using a questionnaire.
Other
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 8, 2026, 2:38 AM EDT
Completed Phase 3 Interventional Results available

A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)

NCT03492281
View directory record Official record
Conditions
Overactive Bladder
Interventions
vibegron, Vibegron placebo, Tolterodine Tartrate ER, Tolterodine placebo
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
1,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
191
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Huntsville, Alabama + 155 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Sep 8, 2026, 2:38 AM EDT
Completed Phase 2 Interventional

Study of AOBO-001 for Overactive Bladder With Urge Urinary Incontinence and Frequency

NCT01294982
View directory record Official record
Conditions
Overactive Bladder
Interventions
AOBO-001, Placebo
Drug
Lead sponsor
American Oriental Bioengineering, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Mobile, Alabama • West Palm Beach, Florida • Newton, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced Sep 8, 2026, 2:38 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate

NCT01777217
View directory record Official record
Conditions
Over-Active Bladder
Interventions
Solifenacin succinate, Placebo
Drug
Lead sponsor
Advanced Research Network
Industry
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Sep 8, 2026, 2:38 AM EDT
Completed Phase 1 Interventional

Phase 1 Study With OAB Assessing the Safety and Activity of hMaxi-K Gene Transfer

NCT01870037
View directory record Official record
Conditions
Overactive Bladder
Interventions
Placebo (PBS-20% sucrose), hMaxi-K
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Garden City, New York • New York, New York • Poughkeepsie, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Sep 8, 2026, 2:38 AM EDT
Recruiting Phase 2 Interventional

RELIEVE Study: NT 201 Intravesical Administration Using Vibe System (ViXe Combination Product) for the Treatment of Idiopathic Overactive Bladder

NCT07553065
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
NT 201 200U and Vibe System, NT 201 300U and Vibe System, Placebo and sham
Combination Product
Lead sponsor
Vensica Therapeutics Ltd.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 8, 2026, 2:38 AM EDT
Completed No phase listed Observational

Urinary Biomarkers For Objective Measurement Of InterStim® Response In Over Active Bladder (OAB) Patients.

NCT01739946
View directory record Official record
Conditions
Overactive Bladder
Interventions
Not listed
Lead sponsor
Michael Chancellor, MD
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 8, 2026, 2:38 AM EDT
Not listed Phase 4 Interventional

BOTOX® at the Time of Prolapse Surgery for OAB

NCT04807920
View directory record Official record
Conditions
Urinary Bladder, Overactive, Pelvic Organ Prolapse
Interventions
OnabotulinumtoxinA 100 UNT, Injectable saline
Drug · Other
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Sep 8, 2026, 2:38 AM EDT
Completed Not applicable Interventional Results available

eCoin for OAB Feasibility Follow-on Study

NCT03655054
View directory record Official record
Conditions
Overactive Bladder, Urge Incontinence, Incontinence, Urinary, Urinary Urge Incontinence
Interventions
eCoin Tibial Nerve Stimulation
Device
Lead sponsor
Valencia Technologies Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Newport Beach, California • Waterloo, Iowa • Greensboro, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2022 · Synced Sep 8, 2026, 2:38 AM EDT
Completed Phase 4 Interventional

A Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder.

NCT00645281
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
tolterodine extended release
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
896 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
96
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 83 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 8, 2026, 2:38 AM EDT
Completed Phase 4 Interventional Results available

A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency

NCT00911937
View directory record Official record
Conditions
Overactive Bladder
Interventions
Fesoterodine, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
963 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
112
States / cities
Mobile, Alabama • Goodyear, Arizona • Litchfield Park, Arizona + 99 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2018 · Synced Sep 8, 2026, 2:38 AM EDT
Completed Phase 4 Interventional Results available

Overactive Bladder Innovative Therapy Trial (OrBIT)

NCT00448175
View directory record Official record
Conditions
Overactive Bladder
Interventions
Urgent PC Neuromodulation System, Tolterodine
Device · Drug
Lead sponsor
Uroplasty, Inc
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minnetonka, Minnesota
Source: ClinicalTrials.gov public record
Updated May 15, 2013 · Synced Sep 8, 2026, 2:38 AM EDT
Completed Phase 4 Interventional Results available

Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life

NCT00573508
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Placebo, Solifenacin Succinate
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
768 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
59
States / cities
Montgomery, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2010 · Synced Sep 8, 2026, 2:38 AM EDT
Completed Not applicable Interventional Results available

Safety and Effectiveness of a Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Overactive Bladder

NCT01369485
View directory record Official record
Conditions
Overactive Bladder
Interventions
(VERV™ System), Sham version of (VERV™ System)
Device
Lead sponsor
Ethicon Endo-Surgery
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
14
States / cities
Tucson, Arizona • Murrieta, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2014 · Synced Sep 8, 2026, 2:38 AM EDT
Completed Phase 3 Interventional

A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB)

NCT00454896
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
VESIcare®, placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
739 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
65
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Atherton, California + 60 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Sep 8, 2026, 2:38 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder

NCT00773552
View directory record Official record
Conditions
Urinary Urge, Urge Incontinence, Overactive Bladder
Interventions
solifenacin succinate, placebo
Drug
Lead sponsor
Stamford Hospital
Other
Eligibility
20 Years to 45 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Sep 8, 2026, 2:38 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genomics and Epigenomics for New Insights in fEmale OAB (GENIE) Study

NCT03057158
View directory record Official record
Conditions
Overactive Bladder, Insulin Resistance
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
257 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2020 · Synced Sep 8, 2026, 2:38 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)

NCT03594058
View directory record Official record
Conditions
Overactive Bladder
Interventions
Solabegron modified release tablets, low dose, Solabegron modified release tablets, high dose, Matching Placebo
Drug
Lead sponsor
Velicept Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
1,413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
77
States / cities
Birmingham, Alabama • Guntersville, Alabama • Saraland, Alabama + 61 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Sep 8, 2026, 2:38 AM EDT
Completed Early Phase 1 Interventional

IVES for Treatment of UUI and OAB

NCT02992509
View directory record Official record
Conditions
Urinary Bladder, Overactive, Urinary Incontinence, Urge
Interventions
EMED detruset(TM) intravesical electrical stimulation
Device
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 3, 2017 · Synced Sep 8, 2026, 2:38 AM EDT